The rally comes after the company announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.

Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary supplement product unbuzzd, investigating its ...

Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover TORONTO, Feb. 04 ...

The surge followed Tuesday's announcement that Quantum had completed a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.

The company is focused on promoting its innovative products, including unbuzzd™, a rapid alcohol detox beverage, and rekvry™, aimed at alcohol misuse treatment. CEO Zeeshan Saeed highlighted ...

Chris Tyson, Executive Vice President at MZ North America, commented, "unbuzzd™ and rekvry™ utilize revolutionary technology that address the issue of excessive alcohol use. The National ...

Results of data analysis show definitively that unbuzzd™ accelerated the rate at which Blood Alcohol Concentration (“BAC”) was reduced in study subjects, while simultaneously reducing the ...

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company ...